To date, there is no specific antiviral therapy for severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) that causes Coronavirus disease 2019 (Covid-19). Since there is no specific therapy against SARS-CoV2, current efforts aim to prevent contagion through public health measures and develop a protective vaccine. While waiting for the latter, it is necessary to evaluate the drugs that at least, in initial studies, suggested some degree of utility in the management of Covid-19 or its complications. The main objective of the study was to describe the clinical manifestations and outcomes of patients with severe Covid-19 Pneumonia treated with corticosteroids and colchicine. A cross sectional study of 301 adult patients with Covid-19 Pneumonia confirmed by Real-Time Polymerase Chain Reaction for SARS-CoV2 (RT-PCR SARS-CoV2), Berlin protocol, who required hospitalization in three hospitals in Antioquia, Colombia. Patients were treated according to the institutional protocol (from March 20, 2020 to June 30, 2020) with corticosteroid if the patient required supplemental oxygen. From July 1, 2020, the management protocol changed with the addition of colchicine to all patients admitted to the institutions. The treatment was supervised and monitored by the same specialist in Infectology of the institutions. We describe the clinical manifestations and outcomes of the patients who received these treatments. The information of the patients was analyzed according to the outcome of interest (alive/dead) with univariate, bivariate, and multivariate measures to adjust the variables that presented statistical association. All patients had pneumonia documented by chest computed tomography with ground glass images and presented an alveolar pressure/inspired oxygen fraction (PaFi) less than 300. Three hundred one patients were included, 240 (79.7%) received corticosteroids, within these 145 (48.2%) received colchicine also, and the remaining 61 (20.3%) patients did not receive corticosterioids or colchicine. Mortality in the group that received colchicine was lower compared to the group that did not receive it (9.6 vs 14.6%, p-value = 0.179). Treatment with corticosteroids and colchicine for managing patients with severe Covid-19 Pneumonia was associated with low mortality at the hospital level. Randomized, placebo-controlled studies are required to evaluate the effect of corticosteroids and colchicine on complications or death from Covid-19.

中文翻译：

---

哥伦比亚接受皮质类固醇和秋水仙碱治疗的 COVID-19 肺炎患者的临床结果

迄今为止，尚无针对导致 2019 年冠状病毒病 (Covid-19) 的严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的特异性抗病毒疗法。由于没有针对 SARS-CoV2 的特定疗法，目前的努力旨在通过公共卫生措施预防传染并开发保护性疫苗。在等待后者的同时，有必要评估至少在初步研究中表明在管理 Covid-19 或其并发症方面具有一定程度实用性的药物。该研究的主要目的是描述使用皮质类固醇和秋水仙碱治疗的重症 Covid-19 肺炎患者的临床表现和结果。通过 SARS-CoV2 实时聚合酶链反应 (RT-PCR SARS-CoV2)，柏林协议，对 301 名成年 Covid-19 肺炎患者进行的横断面研究，谁需要在哥伦比亚安蒂奥基亚的三家医院住院治疗。如果患者需要补充氧气，则根据机构方案（2020 年 3 月 20 日至 2020 年 6 月 30 日）对患者进行皮质类固醇治疗。从 2020 年 7 月 1 日起，管理方案发生变化，所有入院患者均添加秋水仙碱。治疗由同一机构的感染学专家监督和监测。我们描述了接受这些治疗的患者的临床表现和结果。根据感兴趣的结果（生/死），使用单变量、双变量和多变量措施分析患者的信息，以调整呈现统计关联的变量。所有患者都通过胸部计算机断层扫描和磨砂玻璃图像记录了肺炎，并且肺泡压/吸入氧分数 (PaFi) 低于 300。 包括 301 名患者，240 名 (79.7%) 接受皮质类固醇治疗，其中 145 名 (48.2%) ) 也接受了秋水仙碱，其余 61 (20.3%) 名患者未接受皮质类固醇或秋水仙碱。与未接受秋水仙碱组相比，接受秋水仙碱组的死亡率较低（9.6 对 14.6%，p 值 = 0.179）。用皮质类固醇和秋水仙碱治疗严重 Covid-19 肺炎患者与医院水平的低死亡率相关。需要进行随机、安慰剂对照研究来评估皮质类固醇和秋水仙碱对 Covid-19 并发症或死亡的影响。